HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

David J Behm Selected Research

Hypertension (High Blood Pressure)

1/2012Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress.
9/2009Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease.
8/2008Aminomethylpiperazines as selective urotensin antagonists.
6/2007Effects of p38 MAPK Inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production.
1/2007Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors.
4/2005Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: role of systemic blood pressure and endothelial protection.
4/2005Cloning and pharmacological characterization of the cat urotensin-II receptor (UT).
12/2003p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 1. p38 MAPK-dependent endothelial dysfunction and hypertension.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


David J Behm Research Topics

Disease

8Cardiovascular Diseases (Cardiovascular Disease)
07/2013 - 04/2005
8Hypertension (High Blood Pressure)
01/2012 - 12/2003
5Pulmonary Edema
01/2021 - 11/2018
5Heart Failure
01/2021 - 08/2010
4Inflammation (Inflammations)
04/2024 - 12/2003
4Hypertrophy
07/2013 - 04/2005
4Cardiomegaly (Heart Hypertrophy)
04/2013 - 06/2007
3Myocardial Infarction
07/2013 - 08/2010
3Fibrosis (Cirrhosis)
04/2013 - 04/2005
2Atherosclerosis
08/2012 - 06/2009
2Stroke (Strokes)
01/2012 - 09/2009
2Hypoxia (Hypoxemia)
08/2010 - 12/2003
2Albuminuria
04/2005 - 12/2003
2Essential Hypertension
03/2004 - 05/2003
1Acute Lung Injury
04/2024
1Lung Injury
11/2023
1Respiratory Tract Diseases (Respiratory Tract Disease)
09/2021
1Chronic Cough
07/2021
1Cough
07/2021
1Pneumonia (Pneumonitis)
10/2020
1Osteoarthritis
01/2020
1Pain (Aches)
01/2020
1Gastrointestinal Diseases (Functional Gastrointestinal Disorders)
01/2020
1Infarction (Infarctions)
07/2013
1Chronic Obstructive Pulmonary Disease (COPD)
07/2013
1Asthma (Bronchial Asthma)
01/2013
1Bronchial Spasm
01/2013
1Hyperlipidemias (Hyperlipidemia)
08/2012
1Weight Gain
08/2012
1Ischemia
01/2012
1Fatty Liver
05/2011
1Ventricular Dysfunction
08/2010
1Dyslipidemias (Dyslipidemia)
09/2009
1Atherosclerotic Plaque (Atheroma)
06/2009
1Hemorrhage
08/2008
1Shock
08/2008
1Vascular Ring
08/2008

Drug/Important Bio-Agent (IBA)

7urotensin IIIBA
01/2013 - 05/2003
6GSK2798745IBA
04/2024 - 08/2019
4p38 Mitogen-Activated Protein KinasesIBA
09/2009 - 12/2003
3UrotensinsIBA
01/2013 - 08/2008
3SaltsIBA
01/2012 - 12/2003
2Oxygen (Dioxygen)IBA
04/2024 - 08/2010
2Ion Channels (Ion Channel)IBA
09/2021 - 08/2019
2Proteins (Proteins, Gene)FDA Link
10/2020 - 06/2009
2SulfonamidesIBA
12/2018 - 11/2018
2CytokinesIBA
08/2012 - 12/2003
2rho-Associated KinasesIBA
11/2008 - 01/2007
2NG-Nitroarginine Methyl Ester (L-NAME)IBA
08/2008 - 04/2005
2SB-239063ANIBA
04/2005 - 12/2003
2Vasoconstrictor AgentsIBA
03/2004 - 05/2003
1ChlorineIBA
04/2024
1Purinergic P2X ReceptorsIBA
07/2021
1Adenosine Triphosphate (ATP)IBA
07/2021
1Biomarkers (Surrogate Marker)IBA
01/2021
1LipopolysaccharidesIBA
10/2020
1CationsIBA
10/2020
1SulfonesIBA
12/2018
1pyrrolidineIBA
12/2018
1C.I. direct red 80IBA
07/2013
1salicylhydroxamic acid (SHAM)IBA
07/2013
1Atrial Natriuretic Factor (ANF)IBA
07/2013
1Epoxide HydrolasesIBA
07/2013
1CollagenIBA
07/2013
1SmokeIBA
07/2013
1Connective Tissue Growth FactorIBA
04/2013
1N- ((4- bromo- 2- ((trifluoromethyl)oxy)phenyl)methyl)- 1- (4- methyl- 6- (methylamino)- 1,3,5- triazin- 2- yl)- 4- piperidinecarboxamideIBA
04/2013
1N- ((4- cyano- 2- (trifluoromethyl)phenyl)methyl)- 3- ((4- methyl- 6- (methylamino)- 1,3,5- triazin- 2- yl)amino)cyclohexanecarboxamideIBA
04/2013
14'-(1-(((6,7-dichloro-3- oxo- 2,3- dihydro- 4H- 1,4- benzoxazin- 4- yl)acetyl)(methyl)amino)- 2- (4- morpholinyl)ethyl)- 4- biphenylcarboxylic acidIBA
01/2013
1Methacholine Chloride (Methacholine)FDA Link
01/2013
1Bronchodilator Agents (Bronchodilators)IBA
01/2013
1LipidsIBA
08/2012
1Glucose (Dextrose)FDA LinkGeneric
08/2012
1ApolipoproteinsIBA
08/2012
1AdipokinesIBA
08/2012
1BAY 60-4552IBA
01/2012
1Soluble Guanylyl CyclaseIBA
01/2012
1LDL CholesterolIBA
05/2011
1N- ((1- (cyclopropylethyl)- 6- fluoro- 4- hydroxy- 2- oxo- 1,2- dihydro- 3- quinolinyl)carbonyl)glycineIBA
08/2010
1Transcription Factors (Transcription Factor)IBA
08/2010
1Prolyl Hydroxylases (Prolyl Hydroxylase)IBA
08/2010
1Cyclooxygenase 2 (Cyclooxygenase-2)IBA
09/2009
1Interleukin-1beta (Interleukin 1 beta)IBA
09/2009
1rofecoxib (Vioxx)FDA Link
09/2009
1ReninIBA
09/2009
1Anti-Inflammatory Agents (Anti-Inflammatories)IBA
09/2009
1AldosteroneIBA
09/2009
16- (5- ((cyclopropylamino)carbonyl)- 3- fluoro- 2- methylphenyl)- N- (2,2- dimethylprpyl)- 3- pyridinecarboxamideIBA
09/2009
1Niacinamide (Nicotinamide)FDA LinkGeneric
09/2009
1Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA
09/2009
1Apolipoproteins E (ApoE)IBA
06/2009
1BuffersIBA
08/2008
1arginine methyl esterIBA
08/2008
1Ruthenium RedIBA
08/2008
1N- (1- ((4- (2- (((2,4- dichlorophenyl)sulfonyl)amino)- 3- hydroxypropanoyl)- 1- piperazinyl)carbonyl)- 3- methylbutyl)- 1- benzothiophene- 2- carboxamideIBA
08/2008
1Nitric Oxide Synthase (NO Synthase)IBA
08/2008

Therapy/Procedure

2Therapeutics
01/2020 - 04/2013
1Artificial Respiration (Mechanical Ventilation)
04/2024
1Intravenous Infusions
11/2023
1Ligation
08/2010